New drugs are not enough-drug repositioning in oncology: An update
New drugs are not enough-drug repositioning in oncology: An update
复制标题
DOI：
10.3892/ijo.2020.4966
复制
发表时间：
2020-03-01
影响因子：
5.2
通讯作者：
Gomez, Daniel Eduardo
中科院分区：
文献类型：
--
作者：
Armando, Romina Gabriela;Gomez, Diego Luis Mengual;Gomez, Daniel Eduardo
药物重新定位是指发现已知用于治疗其他疾病的药物的新临床益处的概念。这样做的好处是，已经确定了几个重要的药物特性（包括疗效，药代动力学，药效学和毒性），使研究过程中的一个假定的药物更快，成本更低。肿瘤学中的药物重新定位已受到广泛关注。本综述总结了最突出的例子，药物重新定位治疗癌症，考虑到他们的主要用途，提出的抗癌机制和目前的发展状况。
Drug repositioning refers to the concept of discovering novel clinical benefits of drugs that are already known for use treating other diseases. The advantages of this are that several important drug characteristics are already established (including efficacy, pharmacokinetics, pharmacodynamics and toxicity), making the process of research for a putative drug quicker and less costly. Drug repositioning in oncology has received extensive focus. The present review summarizes the most prominent examples of drug repositioning for the treatment of cancer, taking into consideration their primary use, proposed anticancer mechanisms and current development status.